Logo image of YMAB

Y-MABS THERAPEUTICS INC (YMAB) Stock Price, Quote, News and Overview

NASDAQ:YMAB - Nasdaq - US9842411095 - Common Stock - Currency: USD

4.41  +0.3 (+7.3%)

After market: 4.41 0 (0%)

YMAB Quote, Performance and Key Statistics

Y-MABS THERAPEUTICS INC

NASDAQ:YMAB (5/2/2025, 8:00:02 PM)

After market: 4.41 0 (0%)

4.41

+0.3 (+7.3%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High17.47
52 Week Low3.84
Market Cap199.68M
Shares45.28M
Float39.55M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-12 2025-05-12/amc
IPO09-21 2018-09-21


YMAB short term performance overview.The bars show the price performance of YMAB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

YMAB long term performance overview.The bars show the price performance of YMAB in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of YMAB is 4.41 USD. In the past month the price decreased by -5.36%. In the past year, price decreased by -74.29%.

Y-MABS THERAPEUTICS INC / YMAB Daily stock chart

YMAB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.33 351.09B
AMGN AMGEN INC 13.55 151.20B
GILD GILEAD SCIENCES INC 13.4 129.08B
VRTX VERTEX PHARMACEUTICALS INC 1728.1 128.84B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 341.93 39.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.74B
ONC BEIGENE LTD-ADR N/A 27.57B
BNTX BIONTECH SE-ADR N/A 25.23B
NTRA NATERA INC N/A 21.18B
SMMT SUMMIT THERAPEUTICS INC N/A 20.72B
BIIB BIOGEN INC 7.81 18.10B

About YMAB

Company Profile

YMAB logo image Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in Princeton, New Jersey and currently employs 107 full-time employees. The company went IPO on 2018-09-21. The firm is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT), and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas.

Company Info

Y-MABS THERAPEUTICS INC

202 Carnegie Center, Suite 301

Princeton NEW JERSEY 10169 US

CEO: Claus Juan Moller San Pedro

Employees: 104

YMAB Company Website

YMAB Investor Relations

Phone: 16468858505

Y-MABS THERAPEUTICS INC / YMAB FAQ

What is the stock price of Y-MABS THERAPEUTICS INC today?

The current stock price of YMAB is 4.41 USD. The price increased by 7.3% in the last trading session.


What is the ticker symbol for Y-MABS THERAPEUTICS INC stock?

The exchange symbol of Y-MABS THERAPEUTICS INC is YMAB and it is listed on the Nasdaq exchange.


On which exchange is YMAB stock listed?

YMAB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for Y-MABS THERAPEUTICS INC stock?

17 analysts have analysed YMAB and the average price target is 16.13 USD. This implies a price increase of 265.86% is expected in the next year compared to the current price of 4.41. Check the Y-MABS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is Y-MABS THERAPEUTICS INC worth?

Y-MABS THERAPEUTICS INC (YMAB) has a market capitalization of 199.68M USD. This makes YMAB a Micro Cap stock.


How many employees does Y-MABS THERAPEUTICS INC have?

Y-MABS THERAPEUTICS INC (YMAB) currently has 104 employees.


What are the support and resistance levels for Y-MABS THERAPEUTICS INC (YMAB) stock?

Y-MABS THERAPEUTICS INC (YMAB) has a support level at 4.09 and a resistance level at 4.42. Check the full technical report for a detailed analysis of YMAB support and resistance levels.


Is Y-MABS THERAPEUTICS INC (YMAB) expected to grow?

The Revenue of Y-MABS THERAPEUTICS INC (YMAB) is expected to decline by -6.77% in the next year. Check the estimates tab for more information on the YMAB EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy Y-MABS THERAPEUTICS INC (YMAB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does Y-MABS THERAPEUTICS INC (YMAB) stock pay dividends?

YMAB does not pay a dividend.


When does Y-MABS THERAPEUTICS INC (YMAB) report earnings?

Y-MABS THERAPEUTICS INC (YMAB) will report earnings on 2025-05-12, after the market close.


What is the Price/Earnings (PE) ratio of Y-MABS THERAPEUTICS INC (YMAB)?

Y-MABS THERAPEUTICS INC (YMAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.67).


What is the Short Interest ratio of Y-MABS THERAPEUTICS INC (YMAB) stock?

The outstanding short interest for Y-MABS THERAPEUTICS INC (YMAB) is 7.77% of its float. Check the ownership tab for more information on the YMAB short interest.


YMAB Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

YMAB Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to YMAB. The financial health of YMAB is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

YMAB Financial Highlights

Over the last trailing twelve months YMAB reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS decreased by -36.73% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -24.74%
ROE -32.24%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-650%
Sales Q2Q%13.41%
EPS 1Y (TTM)-36.73%
Revenue 1Y (TTM)3.39%

YMAB Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to YMAB. The Buy consensus is the average rating of analysts ratings from 17 analysts.

For the next year, analysts expect an EPS growth of -49.07% and a revenue growth -6.77% for YMAB


Ownership
Inst Owners78.62%
Ins Owners1.96%
Short Float %7.77%
Short Ratio9.08
Analysts
Analysts80
Price Target16.13 (265.76%)
EPS Next Y-49.07%
Revenue Next Year-6.77%